Appeals Court Upholds Invalidity of Acorda’s Ampyra Patents

Drug Industry Daily
A A
A federal appeals court Monday upheld a lower court ruling that invalidated four Acorda Therapeutics patents for the multiple sclerosis drug Ampyra (dalfampridine).

To View This Article:

Login

Subscribe To Drug Industry Daily